Bio-Thera announced yesterday that it has partnered with Cipla Limited in a licensing agreement for its potential bevacizumab biosimilar, BAT1706, referenced on Avastin.
Bio-Thera announced yesterday that it has partnered with Cipla Limited in a licensing agreement for its potential bevacizumab biosimilar, BAT1706, referenced on Avastin.
Under the agreement, Cipla will have exclusive rights to distribute and market the drug in certain emerging markets. BAT-1706 is currently being investigated in a global phase 3 study in patients with previously untreated advanced nonsquamous non—small cell lung cancer. The reference product, Avastin, is currently approved in 6 indications ranging from metastatic colorectal cancer and recurrent glioblastoma, to non-squamous non-small cell lung cancer.
“Bio-Thera is pleased to partner with Cipla to commercialize our lead biosimilar program in select emerging markets. This partnership is an important first step towards making BAT1706, our bevacizumab biosimilar product, availability [sic] globally to help increase patient access to this important cancer therapeutic at affordable prices,” Shengfeng Li, MD, chief executive officer (CEO) of Bio-Thera, said in a statement.
Additionally, through the agreement, Bio-Thera will be responsible for development, product registration with various regulatory agencies, and commercial supply of BAT1706 out of its manufacturing facilities located in Guangzhou, China. Conversely, Cipla will be responsible for the sales and marketing of the product.
“This agreement is in keeping with Cipla’s stated intention to build a strong pipeline of biosimilars through partnerships. We are committed to working towards ensuring patients receive access to life-saving drugs. Through this partnership, Cipla will leverage its strengths in marketing to take this key oncology biosimilar to patients in need,” commented Umang Vohra, MD, global CEO of Cipla.
Bio-Thera also has 2 other potential biosimilars in development: BAT1406, a proposed adalimumab biosimilar, was accepted for regulatory review in October 2018 by the National Medical Products Administration; and BAT1806, a tocilizumab biosimilar that is currently being investigated in late stage clinical trials.
Bio-Thera intends to file BAT1706 for regulatory approval with the China National Medical Products Administration, the European Medicines Agency, and the FDA in 2020.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.